Loading...
Preliminary safety, pharmacokinetics, and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced non-squamous non-small cell lung cancers
PURPOSE: The addition of bevacizumab, an anti-angiogenesis agent, to cytotoxic chemotherapy improves survival in patients with advanced non-squamous non-small cell lung cancers (nsNSCLCs). Regorafenib is an oral multi-targeted kinase inhibitor with potent anti-angiogenic activity that is approved fo...
Na minha lista:
| Udgivet i: | Clin Lung Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4750397/ https://ncbi.nlm.nih.gov/pubmed/26003007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.04.003 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|